An association of VEGFA expression with early recurrence and worse survival of breast cancer has been previously demonstrated, although current data do not support the use of VEGFA levels as a biomarker for guiding antiangiogenic therapy [3,4]. The gene discussed is VEGFA; the disease is breast cancer.